Corresponding Author: Oryan Henig, MD, Department of Infectious Diseases and Infection Control, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel 6423906 (oryanh@tlvmc.gov.il).
Accepted for Publication: December 12, 2021.
Published Online: January 10, 2022. doi:10.1001/jama.2021.23641
Author Contributions: Drs Spitzer and Angel had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Spitzer and Angel contributed equally to the work.
Concept and design: A. Spitzer, Angel, Marudi, Zeltser, Saiag, Goldshmidt, Stark, Gamzu, Feigin, Mizrahi, Yakubovsky, Elkayam, Eviatar, Itzhaki-Alfia, Sprecher, Ben-Ami, Henig.
Acquisition, analysis, or interpretation of data: A. Spitzer, Angel, Marudi, Goldshmidt, Goldiner, Halutz, Slobodkin, Amrami, Elbaz, Furman, Bronstein, Chikly, Eshkol, Furer, Mayer, Meijer, Melloul, Yakubovsky, Rosenberg, Safir, L. Spitzer, Taleb, Elkayam, Silberman, Elalouf, Levinson, Pozyuchenko, Sprecher, Ben-Ami, Henig.
Drafting of the manuscript: A. Spitzer, Angel, Marudi, Saiag, Goldshmidt, Halutz, Slobodkin, Feigin, Elbaz, Furman, Bronstein, Chikly, Mayer, Yakubovsky, Safir, Levinson, Pozyuchenko, Ben -mi, Henig.
Critical revision of the manuscript for important intellectual content: A. Spitzer, Angel, Zeltser, Goldshmidt, Goldiner, Stark, Gamzu, Amrami, Eshkol, Furer, Meijer, Melloul, Mizrahi, Yakubovsky, Rosenberg, L. Spitzer, Taleb, Elkayam, Silberman, Eviatar, Elalouf, Levinson, Itzhaki-Alfia, Sprecher, Ben-Ami.
Statistical analysis: A. Spitzer, Angel, Eshkol, Yakubovsky.
Obtained funding: Goldshmidt, Halutz, Yakubovsky.
Administrative, technical, or material support: Angel, Marudi, Zeltser, Saiag, Goldshmidt, Goldiner, Stark, Halutz, Slobodkin, Amrami, Feigin, Bronstein, Eshkol, Mayer, Meijer, Melloul, Yakubovsky, Safir, L. Spitzer, Taleb, Elkayam, Silberman, Elalouf, Levinson, Pozyuchenko, Itzhaki-Alfia, Sprecher.
Supervision: Zeltser, Goldshmidt, Gamzu, Slobodkin, Mizrahi, Yakubovsky, Elkayam, Levinson, Sprecher, Henig.
Conflict of Interest Disclosures: Dr Angel reported receiving grants from Pfizer outside the submitted work. Dr Goldshmidt reported receiving reagents for the serology tests from Siemens during the conduct of the study. Dr Ben-Ami reported receiving personal fees from Pfizer, Gilead, Teva, and Merck outside the submitted work. No other disclosures were reported.
Funding/Support: The study was funded by the Tel Aviv Sourasky Medical Center. Anti–S1-RBD serology laboratory assays were funded and provided by Siemens. Dr A. Spitzer is partially supported by the Israeli Council for Higher Education via the Weizmann Data Science Research Center, and by a research grant from the estate of Tully and Michele Plesser.
Role of the Funder/Sponsor: Siemens did not have a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the hospital’s employees and students for their participation in the study. We also thank Shabi Shamlo, MA, Lital Zand, MA, Lihi Turgeman, MBA, Avi Ben-Zaken, BSc, ME, Ettie Oziel, BA, Eti Amzel, Tzvi Gregory Avishai, BPharm, MHA, Tanya Grossman, BSc, and Alona Green, MBA, Tel Aviv Sourasky Medical Center, for their administrative assistance and support throughout the study. None of these contributors received compensation for their role in the study.
3.Haas
EJ , Angulo
FJ , McLaughlin
JM ,
et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Lancet. 2021;397(10287):1819-1829. doi:
10.1016/S0140-6736(21)00947-8PubMedGoogle ScholarCrossref 4.Angel
Y , Spitzer
A , Henig
O ,
et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers.
JAMA. 2021;325(24):2457-2465. doi:
10.1001/jama.2021.7152PubMedGoogle ScholarCrossref 8.Self
WH , Tenforde
MW , Rhoads
JP ,
et al; IVY Network. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March-August 2021.
MMWR Morb Mortal Wkly Rep. 2021;70(38):1337-1343. doi:
10.15585/mmwr.mm7038e1PubMedGoogle ScholarCrossref 18.Fowlkes
A , Gaglani
M , Groover
K , Thiese
MS , Tyner
H , Ellingson
K ; HEROES-RECOVER Cohorts. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance—eight US locations, December 2020–August 2021.
MMWR Morb Mortal Wkly Rep. 2021;70(34):1167-1169. doi:
10.15585/mmwr.mm7034e4PubMedGoogle ScholarCrossref 20.Benotmane
I , Gautier
G , Perrin
P ,
et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses.
JAMA. 2021;326(11):1063-1065. doi:
10.1001/jama.2021.12339PubMedGoogle ScholarCrossref 22.Lustig
Y , Sapir
E , Regev-Yochay
G ,
et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lancet Respir Med. 2021;9(9):999-1009. doi:
10.1016/S2213-2600(21)00220-4PubMedGoogle ScholarCrossref 23.Brochot
E , Demey
B , Touzé
A ,
et al. Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals.
Front Microbiol. 2020;11:584251. doi:
10.3389/fmicb.2020.584251PubMedGoogle Scholar 24.Irsara
C , Egger
AE , Prokop
W ,
et al. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
Clin Chem Lab Med. 2021;59(8):1453-1462. doi:
10.1515/cclm-2021-0214PubMedGoogle ScholarCrossref